Ketoconazole (Topical) for Scalp Microbiome

Verdict: Suppresses scalp Malassezia; broad microbiome claims unproven

Topical ketoconazole reliably lowers Malassezia yeast on the scalp and eases dandruff and seborrheic dermatitis, but evidence that it "improves scalp microbiome diversity" as a goal in healthy people is weak and preliminary. Treat it as an antifungal for flaking and itch, not a proven microbiome-balancing product.

C 🟠 C Weak Evidence Published

🔬Why this grade7-layer evidence engine

Only three small studies directly examine ketoconazole and the scalp microbiome. An open-label RCT (n=68, PMID 34416081) found 2% ketoconazole significantly reduced Malassezia (p<0.005), raised fungal diversity, and improved flaking and redness, but it was run and funded by shampoo-makers L'Oreal/Vichy, a notable conflict of interest. A facial cohort (n=45, PMID 35092701) showed shifting fungal diversity but reported no p-values and was not on the scalp.

A 2024 narrative review (PMID 39310465) pooled wider data confirming ketoconazole lowers Malassezia density and improves clinical signs, with one cited trial reporting 89% versus 44% responders on placebo (p<0.01). The clinical antifungal effect is well supported, but no high-quality meta-analysis uses microbiome diversity itself as the main outcome, and total enrollment across these studies is roughly 130 people.

Regulators back the antifungal use, not a microbiome claim: the US FDA labels it for topical use, and the UK NHS calls ketoconazole shampoo the most effective antifungal for seborrheic dermatitis. Clinics such as Cleveland Clinic list it only as a Malassezia treatment and never frame it as microbiome modulation. Because the real evidence covers yeast suppression in flaky-scalp patients rather than broad microbiome balancing, this earns a weak C grade.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.66
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published
Confidence
65%
Broadly consistent
Evidence level
E3
Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L2 PubMedPrimary literature
0.60
L3 MechanismPlausibility
0.65
L5 Clinical bodiesAuthoritative stance
0.85
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.655
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — | B→C 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (3)L2 · primary research & systematic reviews

Continuous clinical improvement of mild-to-moderate seborrheic dermatitis and rebalancing of the scalp microbiome using a selenium disulfide-based shampoo after an initial treatment with ketoconazole
PMID: 34416081 2022 RCT (open-label) n = 68
Finding: Ketoconazole phase produced significant reduction of Malassezia spp. (p<0.005), increased fungal diversity, and improved adherent flakes (-1.75, p<0.05) and erythema (p<0.001).
⚠️ Industry-funded Effect size: Adherent flakes mean change -1.75 (post-ketoconazole vs baseline)
View on PubMed
Ketoconazole 2% cream alters the skin fungal microbiome in seborrhoeic dermatitis: a cohort study
PMID: 35092701 2022 Cohort n = 45
Finding: Post-treatment fungal Shannon diversity and relative abundances of Candida and Aspergillus significantly increased at lesional sites; Malassezia showed decreasing trend (no exact p-values in abstract).
View on PubMed
Ketoconazole Shampoo for Seborrheic Dermatitis of the Scalp: A Narrative Review
PMID: 39310465 2024 系統性回顧 n = 15
Finding: Pooled evidence shows ketoconazole reduces Malassezia density and improves clinical signs; one cited study reported 89% improvement on ketoconazole vs 44% placebo (p<0.01); mechanism extends beyond antifungal to sebum shift and biotin-producing commensal support.
Academic Effect size: Responder rate 89% vs 44% (RR ~2.0) in one cited trial
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
For topical use only source↗
L4c UK NHS
Supportive
Try an antifungal shampoo. Ketoconazole shampoo is the most effective and you can buy it from pharmacies. source↗
L4d TW TFDA / 衛福部
Supportive
Ketoconazole 2% 洗劑(仁山利舒 Nizoral 2% Shampoo)為醫師、藥師、藥劑生指示藥之外用洗髮製劑,適應症為脂漏性皮膚炎、頭皮屑及花斑癬(汗斑);ketoconazole 1% OTC 洗髮精則可於藥局、賣場販售。口服 ketoconazole 因肝毒性風險,食藥署已配合國際同步限縮其全身性使用。 source↗
L5c Cleveland Clinic
Not addressed
These include antifungal drugs such as fluconazole (Diflucan®) or ketoconazole. source↗
L5e Specialty Society (condition-mapped)
Not addressed
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬3 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-scalp-microbiome-INT-ketoconazole-001 繁體中文版 →